Nextstellis sales presented showed that cycle growth has slowed to about 4.5% month on month for 1HF24, this had been growing at about 10% month on month since July 22. January cycles showed an increase of about 11% so maybe we're back on track. The response has been swift though, Daniel Moore EVP Commercial no longer in charge of sales and marketing of WH (now in charge of Dermatology and disintermediation), new person in Lynn Sullivan (previously with Novo Nordisk).
Commentary from CEO:Andit's really about making sure we execute on our plan that we have forNEXTSTELLIS, ANNOVERA, IMVEXXY and BIJUVA. And we weren't fully onplan on our execution. And I guarantee you that's going to change. Soreally, right now, the focus for NEXTSTELLIS and Women's Health isall about our sales and marketing execution and delivering the growthexpectations. So we think we can move it faster with greaterdiscipline in place.
Nextstellis sales presented showed that cycle growth has slowed...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.02 |
Change
0.020(0.40%) |
Mkt cap ! $407.8M | |||
| Open | High | Low | Value | Volume |
| $5.05 | $5.09 | $4.96 | $774.1K | 154.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3317 | $4.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.04 | 1291 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |